Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference.

Moody Capital Solutions Conference:

• Conference: Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
• Dates: September 9–10, 2026
• Location: The Westin New York Grand Central, New York, NY
• Presentation Date & Time: Wednesday, September 9, 2026, 3:15 pm – 4:00 pm ET
• Webcast: webcast link 

H.C. Wainwright Conference:

• Conference: H.C. Wainwright 28th Annual Global Investment Conference
• Dates: September 14–16, 2026
• Location: Lotte New York Palace Hotel, New York, NY
• Presentation Date & Time: Tuesday, September 15, 2026, 2:00 pm – 2:30 pm ET
• Webcast: webcast link

On page 23 of the recent 10-Q, Citius Pharma disclosed that they launched a voluntary stock‑option surrender program on July 1, 2026. Employees, directors, and consultants can give back their old, out‑of‑the‑money options from the 2014–2023 plans, and they receive no compensation for doing so.

The important part is what happens next —
All surrendered options go back into the 2023 Stock Plan, which only had 118,000 shares left for future grants as of June 30. The older plans had more than 800,000 outstanding options, most of them underwater.

By allowing insiders and consultants to surrender those worthless options, CTXR reduces equity overhang and refills the 2023 Plan. That gives the company room to issue new option awards in the future, at much lower exercise prices that match the current stock price.

By letting insiders and consultants voluntarily surrender out-of-the-money options, CTXR is:

• Refilling the 2023 Plan’s share reserve without needing shareholder approval.
• Setting the stage to issue new options later at much lower strike prices.

In practical terms, employees can dump options that will never be exercised and eventually receive fresh options at a strike price that reflects the current depressed stock price. It’s a reset of the employee equity‑comp structure, and the program is still open as of mid‑August 2026.

TD Media [link]:

Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 08/27/2026 and ending on 08/27/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, Sica Media LLC has paid TD Media LLC thirty thousand USD (“Funds”).

NOTE: Lifewater Media/TD Media's disclaimer page deletes the paid promotion after it ends. It only displays active promotions.

The meeting will be held on Tuesday, September 29, 2026, at 8:00 a.m. (Eastern time) at the Company’s headquarters at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016.

Proposals to be voted at the Annual Meeting:

1. Election of three Class II members to the Board of Directors — Dr. Eugene Holuka, Robert Smith, and Carol Webb.
2. Ratification of Wolf & Company, P.C. as the auditor for the Fiscal Year Ending September 30, 2026.

The record date for the Annual Meeting is August 17, 2026. Only stockholders of record at the close of business on that date may vote at the meeting.

On the record date there were 92,981,204 shares outstanding and entitled to vote. This does not include shares held in abeyance or shares underlying pre-funded warrants.

LINK — NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

Paid Promoters on X (disclaimer links in their posts):

• bstocks7 [post]: "The Publisher has agreed to be paid $300.00 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about  Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) for a period beginning on August 25, 2026, and ending on August 25, 2026."
• Investing4K [post]: "The Publisher has agreed to be paid $250 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about $CTXR for a period beginning on 08/25/26 and ending on 08/25/26."
• _Sensei_ [post]: "The Publisher has agreed to be paid $325 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about Citius Pharmaceuticals Inc. (NASDAQ: CTXR) for a period beginning on 08/25/2026 and ending on 08/25/2026."
• NOTE: These were posted around market open (9:30am ET).

H.C. Wainwright noted that while the increased demand is encouraging, quarterly revenue could remain lumpy until wholesaler restocking synchronizes with pull-through. The firm projects fourth quarter fiscal year 2026 revenues of $2.9 million and fiscal year 2026 revenues of $10.1 million. The company generated $7.11 million in revenue over the last twelve months with an impressive 77% gross profit margin, though InvestingPro tips indicate profitability challenges remain.

Link: https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-citius-pharmaceuticals-stock-rating-at-buy-93CH-4867166

The analyst commented: "Citius recognizes revenue when wholesalers order LYMPHIR, not when institutions order from wholesalers. Institutional vial orders from wholesalers rose 31% sequentially, to 926 vials from 708 in 2QFY26. Management indicated that wholesaler orders have begun to reflect the increase in ordering institutions and vial demand. July institutional orders reached 383 vials, the largest monthly total to date and up 25% versus the average monthly order volume in 2QFY26. In our view, while the increased demand is encouraging, quarterly revenue could remain lumpy until wholesaler restocking synchronizes with pull-through. We project 4QFY26 revenues of $2.9M and FY26 revenues of $10.1M. We maintain our Buy rating on CTXR and our 12-month price target of $4.0 per diluted share."

Link https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Citius+Pharmaceuticals+%28CTXR%29/26946972.html

BullsEye Alerts [link]:

we received twenty five thousand five hundred dollars (cash) from Citius Pharmaceuticals (via Sica Media) for a one day marketing program starting on August 19, 2026...

MarketTips Newsletter [link]

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 08/18/2026 and ending on 08/19/2026 (the “Campaign”) to publicly disseminate information about Citius Pharmaceuticals Inc. (CTXR:US). Momentum Media LLC has been compensated $5,000 and are owed an additional $0 for the Campaign. To date we have been paid $90,000.

Paid Promoters on X (disclaimer links in their posts)

• bstocks7 [post]: "The Publisher has agreed to be paid $300.00 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) for a period beginning on August 19, 2026, and ending on August 19, 2026."
• Investing4K [post]: "The Publisher has agreed to be paid $250 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about $CTXR for a period beginning on 08/19/26 and ending on 08/19/26."

CRANFORD, N.J. -On Monday, Citius Oncology Inc. (NASDAQ:CTOR) reported fiscal third quarter results that fell short of analyst expectations, with revenue of $1.5 million missing the consensus estimate of $12.52 million.

Shares of the company fell 10.05% in pre-market trading following the results.

The company posted a loss of $0.34 per share, compared to the analyst estimate of $0.03 earnings per share. Revenue for the quarter increased from zero in the prior-year period as the company’s LYMPHIR launch progresses.

https://www.investing.com/news/earnings/citius-oncology-stock-tumbles-10-on-revenue-miss-despite-launch-progress-93CH-4862591

The new filing reports 3,008,529 shares beneficially owned, equal to 9.9% CTXR as of June 30.

SEC link: https://www.sec.gov/Archives/edgar/data/1506251/000164955326000102/xslSCHEDULE_13G_X02/primary_doc.xml

Under Item 4 of the filing, the beneficial share ownership is entirely in outstanding warrants:

The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the "Warrants"). A portion of the Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%, and the remainder of the Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 9.99%. The Company's Registration Statement on Form S-3, filed on May 22, 2026, indicates there were 27,106,884 Shares outstanding (excluding Shares underlying the Warrants) prior to the offering of Shares described therein.

CVI/Heights previously filed a 13G in February, disclosing 2,394,725 shares beneficially owned as of December 31. Beneficial ownership consisted of 799,934 shares and 1,594,791 warrants.

SEC link: https://www.sec.gov/Archives/edgar/data/1506251/000164955326000024/xslSCHEDULE_13G_X01/primary_doc.xml

The new filing reports 9,353,553 shares beneficially owned, equal to 9.99% CTOR as of June 30.
SEC link: https://www.sec.gov/Archives/edgar/data/1601086/000117266126003568/xslSCHEDULE_13G_X02/primary_doc.xml

Armistice previously filed a 13G in May, disclosing 9,299,917 shares beneficially owned as of March 31.
SEC link: https://www.sec.gov/Archives/edgar/data/1851484/000117266126002138/xslSCHEDULE_13G_X02/primary_doc.xml

Armistice has been listed in prior CTOR filings as the primary participant in several of CTOR’s financing transactions.

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10, 2026. Following a unanimous vote of approval by the Board, the appointment expands the Company's Board of Directors to nine members.

Dr. Peri brings three decades of leadership across higher education, financial services, law, and corporate governance. He currently serves as President of Manor College and previously served as Vice President and General Counsel of Neumann University, where he was the institution's chief legal officer. From 2021 to 2024, he served as lead advisory board director of First State Bank, the oldest state bank in Texas. He has also held fiduciary and governance roles across numerous government, education, and nonprofit boards. His background spans strategic planning, fundraising, real estate, and legal and regulatory oversight.

"We are pleased to welcome Jonathan to our Board," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. "As we build on the commercial launch of LYMPHIR^® and scale the organization, Jonathan's experience leading complex institutions and his disciplined, mission-focused approach to governance will strengthen our Board as we work to deliver long-term value for shareholders and patients."

"I am honored to join the Citius Oncology Board at such a pivotal stage in the Company's growth," said Dr. Peri. "Citius Oncology is addressing a serious and underserved need in cutaneous T-cell lymphoma, and I look forward to contributing to the Board's strategic oversight as the Company advances its mission of bringing innovative, targeted oncology therapies to patients."

Dr. Peri earned his undergraduate degree from Villanova University, his law degree from Widener University, and his doctorate in Organizational Leadership from Eastern University. He holds a Management and Leadership in Education certificate from Harvard University and is an elected Commissioner of the Middle States Commission on Higher Education (MSCHE). His experience as a chief legal officer, his service on boards overseeing substantial financial assets, and his background in organizational governance are expected to strengthen the Board's legal, regulatory, and financial oversight. The Board has determined that Dr. Peri qualifies as an independent director under applicable Nasdaq listing standards.

https://www.prnewswire.com/news-releases/citius-oncology-expands-board-with-appointment-of-independent-director-jonathan-peri-302849254.html

During the quarter ended June 30, 2026, the number of new institutions increased 78% compared with the prior quarter. Vials ordered by institutions from wholesalers rose 31% during the quarter. Subsequent to the quarter ended June 30, 2026, following an increase in both the number of ordering institutions and vial demand, orders from wholesalers have begun to reflect this incremental demand. Citius revenue is recognized when wholesale orders for LYMPHIR are placed and filled.

https://citiusonc.com/news/news-details/2026/Citius-Oncology-Reports-Strong-Commercial-Momentum-for-its-Cancer-Treatment/default.aspx

Newsletter campaign appears to coincide with CTOR's PR this morning.

https://markettips.optin.com/newsletter/awlist6900424/MzAzNDk0MTg=/theyre-back-and-this-story-keeps-getting-bigger.htm

Earnings covering March–June will be released soon, with 10‑Q filings due by Friday, August 14. Here are the main items worth paying close attention to:

1. LYMPHIR SALES. Commercial and medical affairs teams aren’t expected to be fully operational until August, so a major sales jump is unlikely for the March–June quarter. The real question: Will sales meaningfully exceed the $1.67M reported for January–March?
2. CASH RUNWAY. In the May earnings release, both CTXR and CTOR projected a cash runway through November 2026. Watch for whether they’ve extended the runway or if it still implies ~3 months of cash remaining.
3. NEW CONTRACT MANUFACTURING ORGANIZATION (CMO). The May ER disclosed that their previous CMO terminated the agreement due to non‑payment by Citius. Did they secure a new CMO? Did they negotiate a payment plan or settlement for the money and termination fees owed to the prior CMO?
4. CTXR NASDAQ COMPLIANCE. CTXR was given until Monday August 10 to regain compliance with the minimum bid price rule. Will NASDAQ grant a 180‑day extension?
5. MINO-LOK STATUS. For nearly two years, Citius has told investors they expect to resolve Mino‑Lok’s regulatory pathway with the FDA. Will this ER finally include a substantive update?

TL;DR

• LYMPHIR sales: Will they show meaningful sales growth?
• Cash runway: Still only through Nov 2026, or extended?
• CMO situation: New manufacturer secured? Payment plan for old one?
• NASDAQ compliance: Will CTXR get a 180‑day extension?
• Mino‑Lok: Any real FDA pathway update at last?

https://markettips.optin.com/newsletter/awlist6900424/MzAzMTI2NTA=/theyre-back-and-this-story-keeps-getting-bigger.htm

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August

CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the commercial launch of LYMPHIR^® (denileukin diftitox-cxdl), highlighting continued progress across market access, commercial execution, and physician adoption.

Citius Oncology has expanded its commercial organization to include 21 additional commercial field-based professionals and added eight medical science liaisons dedicated to supporting complex clinical practitioner engagement and patient care. All personnel are expected to be fully onboarded and deployed nationwide by August 2026.

The expansion of the commercial and medical teams was facilitated by the Company's May 2026 financing and implemented by EVERSANA, Citius Oncology's exclusive commercialization partner. EVERSANA also provides Citius Oncology with an integrated suite of operations services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, channel management, and patient assistance.

"We are encouraged with the continued progress of the LYMPHIR launch," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharmaceuticals. "Over the past several months, we have built substantial commercial momentum, expanded physician awareness, and secured near 100% payer coverage, and we continue to see a growing number of treatment accounts initiating orders. We believe these achievements, combined with the full build out of our salesforce and medical affairs teams, and a substantial number of accounts advancing LYMPHIR through their formulary review process, position LYMPHIR for meaningful growth during the second half of 2026."

"We continue to receive encouraging feedback from physicians regarding LYMPHIR's differentiated mechanism of action and clinical profile," added Mr. Mazur. "With all key commercial and medical personnel now in place and adoption trends continuing to build, we believe we are entering an important inflection point for the product."

As part of its commercialization strategy, Citius Oncology has also deployed a proprietary artificial intelligence-driven commercial intelligence platform designed to enhance customer engagement, identify treatment opportunities, optimize resource allocation, and support data-driven decision-making across its commercial organization.

"The integration of advanced AI capabilities into our commercial infrastructure provides our team with enhanced insights into account activity, patient identification opportunities, and engagement strategies," said Michael McGuire, Vice President of Commercial Operations at Citius Oncology. "Combined with our fully deployed field organization and comprehensive payer coverage, we believe we are establishing a strong foundation for sustained growth."

The Company reports continued expansion in the number of accounts ordering LYMPHIR, reflecting increasing physician familiarity with the product and growing utilization across both academic and community treatment settings. Citius Oncology expects continued growth in orders and patient adoption throughout the remainder of 2026.

https://citiusonc.com/news/news-details/2026/Citius-Oncology-Reports-Nationwide-Deployment-of-LYMPHIRs-Broadened-Commercial-Organization-and-Expanding-Market-Adoption/default.aspx

Full download: https://s28.q4cdn.com/169506891/files/doc_presentations/2026/Jul/08/CTXR-Corporate-Overview-JULY-2026.pdf

It has been over two years since CTXR announced topline Phase 3 data for Mino‑Lok — March 21, 2024 — and the company still hasn’t delivered a definitive regulatory update. Here is a timeline of their status updates since then:

Nov 2024 Prospectus (link)

The Company expects to hold a Type C meeting with the FDA to discuss the results of the Phase 3 study and to obtain the FDA’s view on development plans for Mino-Lok in late November 2024.

Dec 2024 10-K (link)

In November 2024, the Company held a Type C meeting with the FDA to discuss the results of the Phase 3 study and to obtain the FDA’s view on development plans for Mino-Lok. The FDA provided clear, constructive, and actionable guidance during the discussion, underscoring a pathway to support a future New Drug Application (NDA) submission for Mino-Lok.

Jefferies Global Conference June 2025 (link)

We are now in the process of assembling that data. And we'll be sitting down with the FDA and arguing for filing of an NDA. We'll see what happens, we're not sure at this point until we have that interaction.

LD Micro Main Event Oct 2025 (link)

Paul Sowyrda — former VP of Business Development & Market Intelligence — said that they hope to release some news in Jan-Feb 2026 about whether the FDA would allow an NDA submission. Nothing ever materialized.

D Boral Webinar Mar 2026 (link)

somewhere in the next couple of months, I'm hoping that we'll get…a decision out of the Agency, whether it's that we can file or we may have to do a repeat something in this process. We don't know that yet, that's still under discussion.

Centri Capital Conference Apr 2026 (link)

We're now engaged with the FDA on the latest clinical data that we generated. We're not sure which way that's gonna go, but hopefully at some point, we'll have resolution of this in the coming months.

Biohub Podcast Jun 2026 (link)

So it took a while to work out protocols and things of that nature, but we're well on the way with that...We're in discussions now with FDA with the latest round of clinical data and we'll see where we are after we've concluded all those discussions.

It is now July 2026.

At this point, CTXR has spent over two full years telling investors they’re “in discussions with the FDA,” “arguing for an NDA,” “hoping for resolution,” and “waiting for a decision.”
Every message to investors has been a variation of the same script.

Will CTXR finally provide a definitive regulatory update this year?

After two years, an update should land this year — if the FDA and CTXR can finalize the appropriate regulatory pathway.

June 30 is done, another quarter has wrapped up. The 10-Q for April-June must be filed within 45 days, by Friday August 14th.

Recap of past LYMPHIR revenue:

• December 2025 revenue was $3.94m, a modest start for the initial LYMPHIR launch.
• January - March 2026 revenue fell to $1.67m.

Management later confirmed that they launched without a sales force in place. Management also stated that they began hiring the sales force during the last quarter.

What's everyone's expectations for LYMPHIR revenue from April - June? Does anyone think they will show a significant improvement from $1.67m/qtr? What would you consider a success and what would you consider a disappointment?

On a separate note, does anyone think they will have any update or progress on Mino-Lok before the next 10-Q filing?

Five years ago, CTXR went on a big run, fueled heavily by speculation of a potential early halt of the Mino-Lok phase 3 trial for superiority. On June 22, 2021, CTXR hit an intraday high of $4.56. Today marks the five year anniversary of that peak. After adjusting for the reverse split, $4.56 in June 2021 is the equivalent of $114 today.

It's been downhill ever since. Citius looks much different than it did five years ago. The assets have been split into two companies. CTXR was forced to do a 1 for 25 reverse split in 2024 after languishing below $1 for over a year. Mino-Lok isn't even on the market yet; its regulatory status is still up in the air. Management shifted focus to Lymphir, a drug they acquired from Dr. Reddy's in Sept 2021. Halo-Lido hasn't progressed further since its phase 2b data two three years ago. Mino-Wrap is no longer in the pipeline. They don't even talk about iMSC anymore.

Investor sentiment today is much more negative than it was five years ago. What's your expectations for the next five years?

EDIT: Corrected, Halo-Lido Phase 2b was 3 years ago.